

Numinus

At the forefront of addressing
the universal desire to heal

Investor presentation
September 14, 2020

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to operate and expand the Company’s facilities; engaging in activities which currently are illegal under Canadian federal law and the uncertainty of existing protection from Canadian federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry as well as the use of psychedelic therapies, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, including closing of the financings contemplated herein; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.



We address the universal desire to heal.

Numinus is an operating company at the forefront of the transformative change in addressing the growing prevalence of mental health issues and desire for greater wellness.

Our unique growth platform includes a testing and research facility that can support the emerging market of psychedelic-assisted psychotherapies to supplement existing options in addressing mental illness, addictions and PTSD, as well as a fully integrated wellness centre model we aim to scale globally.

Cannabis revenue through our laboratory and production operations will help fund our growth plans.

Numinus was created from the merger of Salvation Botanicals and Numinus Wellness Inc. and went public via an RTO with Rojo Resources in Q2 2020 under the symbol NUMI.

Licensed
by Health Canada to
test, sell, and
distribute psychedelic
substances.

Psychedelic-assisted psychotherapies have been designated *breakthrough therapy** status by the FDA in treatment, and we are on top of the next wave in addressing a growing trend of mental health issues in Canada and around the world.


Early-mover advantage: Numinus is the first publicly traded company in Canada granted a licence by Health Canada to conduct research into the production and extraction of psilocybin from mushrooms. We will play an important role in the areas of psychedelic substances research, testing, and global distribution.

We can test, possess, buy, and sell MDMA, psilocybin, psilocin, DMT, and mescaline. We have applied to amend our licence to soon include activities such as R&D, import/export, and packaging/labelling to become the leading psychedelics drugs marketing and distribution company.

* U.S Food and Drug Administration (FDA) designation that expedites the development and review of drugs intended to treat a serious condition

Transformative change is needed

There are epidemic rates of addiction, mental illness, and physical ill health. Despite climbing patient costs, more work is needed to supplement existing options.



\$51B

Estimated annual economic burden of mental illness in Canada

1 in 2

The number of Canadians who will be affected by mental health issues by the age of 40

4,000

The number of Canadians who die by suicide per year – almost 11 suicides per day

9%+

Percentage of Canadian adults who will suffer PTSD in their lifetime

500,000

Number of unemployed Canadians who are unable to work due to mental health problems

1 in 5

The number of Canadians who suffer from addiction in any given year

50%

Percentage of Canadians experiencing a major depressive episode that do not receive “potentially adequate care”

#4

Canada’s rank in the use of antidepressant drugs per capita. The use of antidepressants is on the rise globally.

The use of psychedelic-assisted psychotherapies in a safe, controlled, therapeutic environment is moving to the mainstream.




- [Decriminalization](#) of psilocybin in Denver and Oakland and similar legislation being discussed in Portland.
- FDA grants breakthrough therapy designation to [COMPASS PATHWAYS](#) for psilocybin-assisted psychotherapy for treatment-resistant depression.
- FDA grants breakthrough therapy designation to [MAPS](#) for MDMA-assisted psychotherapy for the treatment of PTSD.
- [BC Centre on Substance Use](#) commencing Phase III clinical trials of MDMA for patients suffering from PTSD.
- FDA grants breakthrough therapy designation to [Usona Institute's](#) psilocybin program in the treatment of major depressive disorder.
- [Johns Hopkins](#) opening a new US\$17M centre for psychedelic research.


Our addressable market

1. The growing number of those suffering from PTSD, addictions and mental health issues looking to supplement existing options.
2. All people who will be attracted to the services offered through Numinus Wellness



We are in-market and fully integrated – from lab facility through to our wellness centre model – to serve the psychedelic-assisted psychotherapy space.






Numinus Bioscience Testing & research facility

- 7,000 sq. ft. fully built and paid for testing and research facility.
- We are licensed by Health Canada to produce and extract psilocybin from mushrooms. Our licence also allows us to test, possess, buy, and sell MDMA, psilocybin, psilocin, DMT, and mescaline.
- Staffed by internationally-acclaimed PhDs with backgrounds in peer-reviewed research, pharmaceutical manufacturing and advanced analytical technologies.
- Utilizing proprietary technology and chromatography, spectroscopy, and mass spectrometry techniques.

Numinus Wellness

- Acquired an operational facility in 2019 aligned with our model that embraces the exploration of evidence-based use of psychedelic therapies (these therapies are not in use today at our Vancouver facility and will only proceed when approved by regulators).
- Dedicated to providing access to safe, controlled, therapeutic environments for treatments that enhance and supplement existing options.
- Based on learning from the existing facility, the company plans to identify and lease space for a planned purpose-built facility in Vancouver.
- The company also plans to acquire additional facilities where a patient-focused model can be applied.



We are not a concept.
We are a growth
story.

2020 Runway

- Numinus listed on TSX-V through RTO in Q2 2020 (symbol: NUMI).
- Estimated 2020 revenues from testing/research facilities and healing centre: ~\$3M.
- Standard processing/extraction licence by Health Canada expected in Q4 2020.
- Expand our wellness centre footprint and brand:
 - Identify location for purpose-built, flagship wellness centre in Vancouver.
 - Acquire and integrate 2-4 existing wellness centres in Canada aligned with our model.
 - Receive inputs from MAPS and research professionals on space/clinic requirements for trials.
- Granted amendment to Health Canada licence under the Controlled Drugs and Substances Act to produce and extract psilocybin from mushrooms
- Advance therapeutic, evidence-based patient studies in psychedelic therapies (MOU signed with BC Centre on Substance Use).

Cannabis revenue to help fund growth

Revenue from our cannabis testing and production operations provides us a foundation for growth – differentiating us from others in the psychedelics space.

Our fully built and paid for facility has the capacity to take on THC and CBD product and is set to be a progressive player in the cannabis extraction market upon issuing of its standard processing licence by Health Canada, expected in Q4 2020.



**Final Extract
Product Capacity**

375 million
mg / year

**Cannabis
Tests**

100,000
/ year

**Estimated Annual
Potential Revenue***

\$25M

* Estimate dependent on timing of receiving Health Canada processing licence, production facility operating at capacity and favourable market conditions.

Fund Raising and Use of Proceeds

Between December 2019 and March 2020, the Company (on a consolidated basis) raised a total of \$6,800,000 through the following:

- Subscription Receipt Financing \$5,745,000
- Sidecar Financing \$255,000
- Private Placement Financing \$800,000

Numinus intends to use the proceeds to advance our 2020 targets, including:

- Partnership with BC Centre on Substance Use
- Psychedelic protocol research and development
- Upgrade Numinus Bioscience lab and processing facility upon receipt of Health Canada licences
- Identify and develop purpose-built facility
- Clinic acquisitions



Executive Team



PAYTON NYQUEST
Chairman & CEO

Former Director, VP and Head of Sales at Mackie Research Capital, one of Canada's largest independent brokerage firms with a focus on public health and human advancement. Fifteen years experience in investment banking, has raised over \$100 million for 100+ public and private companies. Former investment advisor with Jordan Capital Markets, Canaccord Financial.



DR. EVAN WOOD,
MD, PhD, ABIM, FASAM,
FRCPC, ABAM Diplomat
Chief Medical Officer

Recognized researcher with 20+ years of experience in addiction research, most recently as Executive Director of the British Columbia Centre on Substance Use (BCCSU). Professor of medicine at the University of British Columbia. Work on psychedelic-assisted psychotherapy includes involvement with the Multidisciplinary Association for Psychedelics Studies (MAPS) trial of MDMA assisted psychotherapy and examining the potential of psilocybin assisted psychotherapy for a range of mental health disorders.



JOHN FONG
Chief Financial Officer

Experienced financial operator growing technology companies for the past five years, most recently as Managing Director of Invoke Digital. Prior to that, spent 15 years building international financial operations with companies listed on the TSX, NYSE, London AIM and Lima Stock Exchange, the highlight of which was being on the founding team of Rio Alto Mining, a gold company that in three years went from exploration stage to generating net income of \$100 million and operating cash flow of \$98 million in its first year of commercial production.



MICHAEL TAN
Chief Operating Officer

Former/first executive director, BCLDB Cannabis Division. Successfully launched Cannabis operations in BC. Twenty years' strategic planning and execution with national and multinational corporations. High-impact product development, marketing and operations executive with a track record of driving profitable revenue growth.



STACEY WALLIN
Chief Strategy Officer

Former Founder and CEO of LifeBooster, a tech startup now helping Fortune 100 clients detect and proactively respond to workplace injury risks. Most recently was the Director of Venture Programs at the BC Tech Association, leading the team developing accelerators for scale companies in BC with a mandate of solving the largest ecosystem and policy-related challenges facing growth and scale stage technology companies. Also founded and runs the Canadian Accelerator Incubator Network.



KRAIG DOCHERTY
Chief People Officer

20-years of experience in strategic HR, Operations and Talent positions scaling high growth companies including Electronic Arts, Activision Blizzard, Indochino, Invoke and Eventbase. Recruited and hired over 1000 professionals globally. Experience spanning human resources, culture building, recruiting and talent acquisition, employment branding, office design and construction and community building.

Leadership Team



DR. DEVON CHRISTIE, MD, CCFP
Medical Director and Member of
Clinical Advisory Council

Family physician with a focused practice in Multidisciplinary Pain Management and Registered Therapeutic Counsellor, emphasizing Relational Somatic Therapy for trauma resolution. Teacher in the Certificate in Psychedelic-Assisted Therapies and Research post-graduate program at the California Institute of Integral Studies (CIIS).

Trained to deliver MDMA-assisted psychotherapy for PTSD (MAPS USA) and ketamine-assisted psychotherapy in a research setting. Expert on the potential of incorporating psychedelic-assisted psychotherapies in an integrated healthcare model.



JUDY VARGA, M.Sc.
Head of Laboratory Operations

Analytical chemist with experience in pharmaceutical industry.

GMP/GLP, QC Lead with major Canadian LP for two years.

Advanced microbiology methods



**DR KRISTINA GROTZINGER,
PhD, B.Sc.**
Senior Research Scientist

20 years of phytochemistry experience in regulated lab environments.

Health Canada-certified Qualified Person in Charge (QPIC).

SR&ED projects (2013 – present) in analytical methods for cannabis testing.

Avid researcher and lecturer in natural health/herbal medicines and author of peer-reviewed research papers.



DR BERND O. KELLER, PhD
Senior Research Scientist

Over 20 years experience in advanced analytical technologies and methods.

Authored 30 peer reviewed publications.

Former research scientist of Child & Family Research Institute, BC Children's Hospital.

Former director of mass spectrometry facility at Queens University.

Path to Public

- Salvation acquired Numinus in Q4 2019.
- Definitive RTO arrangement agreement signed by Salvation Botanicals and Rojo Resources in October 2019.
- Total of \$6.8M raised ahead of public listing in Q2 2020:
 - Over-subscribed private placement: \$800,000 raised as of December 2019 close, well above \$650,000 target and at the limit of the TSXV's overall allotment policies.
 - Subscription receipt offering and sidecar private placement: \$6M raised in total as of March 9, 2020 close, well above initial \$4M target.
- The company was listed on the TSX Venture Exchange in May 2020 and the company was renamed Numinus Wellness Inc. (TSX-V: NUMI)



Path to Public

Numinus Wellness Inc.

Rojo Resources Shares	3,786,543
Rojo Shares issued at \$0.25 for \$800,000 private placement	3,200,000
Salvation Shares Issued at \$0.32	1,739,380
Salvation Shares Issued at \$0.50 ⁽¹⁾	19,620,990
Subscription receipt financing at \$0.25	22,980,000
Sidecar financing at \$0.25	1,530,000
Insider/Founder Shares ⁽²⁾	42,194,459
Total Outstanding Shares	95,051,371

⁽¹⁾ Includes 10,134,593 Salvation Special Warrants at \$0.50

⁽²⁾ Includes 2,000,000 shares issued by Salvation for acquisition of Numinus and 2,320,000 shares issued for conversion of Numinus convertible debentures

The Company has 35,050,840 shares in escrow priced at and will be released as follows:

Release Schedule

Escrow Shares Details	Shares between \$0.01 to \$0.10	Shares between \$0.11 to \$0.25	Shares between \$0.26 to \$0.50	Total
May 15, 2020	2,876,718	469,726	158,640	3,505,084
Nov 15, 2020	4,315,077	704,589	237,960	5,257,626
May 15, 2021	4,315,077	704,589	237,960	5,257,626
Nov 15, 2021	4,315,077	704,589	237,960	5,257,626
May 15, 2022	4,315,077	704,589	237,960	5,257,626
Nov 15, 2022	4,315,077	704,589	237,960	5,257,626
May 15, 2023	4,315,077	704,589	237,960	5,257,626
Total	28,767,180	4,697,260	1,586,400	35,050,840

N

33 Water Street – Suite 801
Vancouver, BC V6B 1R4

1.833.686.4687

numinus.ca

A preliminary short form prospectus containing important information relating to the securities described in this document has not yet been filed with the securities regulatory authorities in each of the provinces of Canada. A copy of the preliminary short form prospectus is required to be delivered to any investor that received this document and expressed an interest in acquiring the securities.

There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final short form prospectus has been issued.

This document does not provide full disclosure of all material facts relating to the securities offered. Investors should read the preliminary short form prospectus, final short form prospectus and any amendment, for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision.

